Fragment based drug discovery has become an important tool for finding hit compounds for difficult targets. The technique utilizes smaller than drug-like compounds to identify low potency, high quality leads. Libraries containing hundreds to thousands of compounds achieve similar coverage of chemical space as the millions required for the traditional high throughput screening campaigns.
As one of the leading compound management and aggregation services provider for the drug discovery community, Specs sourced and assembled a fragment-based library as part of the Horizon2020 funded EU-OPENSCREEN-DRIVE project to the EU-Openscreen facilities in Berlin, Germany, for screening against SARS-CoV-2 targets. In total, 968 low-molecular-weight fragments from 5 different suppliers were plated as 100 mM DMSO-d6 solution in the LVL Safe-LX1000-Data Matrix Tube EU-Openscreen standard format. In addition, 88 ultra-low-molecular-weight compounds (so called minifrags) from 8 different suppliers were delivered as powders in 1Dram vials. Furthermore, 6 small-volume copies in 1536 well Echo compatible screening plates were supplied to one of the iNEXT-discovery partners in Didcot, UK. Read more on the current use of this library on the site of EU-OPENSCREEN.
Specs also has her own pre-plated fragment library, applying Astex rule of 3 filters in combination with our in-house property algorithms. 4,536 compounds with a molecular weight of less than 300 Dalton are available off-the-shelf in 96 well plates and from solid stock for follow-up activities. More information can be found in this factsheet.
If you are interested in Specs compound management and aggregation services or in the above-mentioned fragment library for your research, do not hesitate to contact us at firstname.lastname@example.org.
published on: 13-Oct-20